Sydney, Feb 11, 2008 (ABN Newswire) - Ventracor (ASX: VCR)(US: VTCRY) has implanted the 200th patient with its VentrAssist(tm) Left Ventricular Assist Device (LVAD).
There are now 28 centres worldwide who have implanted the VentrAssist. Commenting on this achievement, the CEO of Ventracor, Mr Peter Crosby, said: "We are really pleased that the potential of the VentrAssist continues to be recognized, and that our life saving technology has contributed to so many people worldwide".
"The clinical results continue to be very encouraging and as our experience grows, we remain optimistic that the end points of our US clinical trials will be met" Mr Crosby added.
In the US, 34 patients have been recruited in the Bridge to Transplant (BTT) Clinical Trial (out of a total of approximately 140 patients) and 14 patients recruited in the Destination Therapy (DT) Clinical Trial (out of a total of approximately 225 patients). There are now 18 US centres trained and ready to recruit in each of the trials.
Half year results for Ventracor will be announced on 22 February, 2008. A conference call to discuss the results will be held at 10.00 am on 22 February 2008. Please contact Angela Edwards, Investor Relations on +61(2)9406 3100 for details.
Ventracor is a global medical device company which produces an implantable blood pump, the VentrAssist left ventricular assist device (LVAD), as a therapy to improve the lives of heart failure patients. Ventracor is dedicated to building partnerships with healthcare professionals to make the VentrAssist the standard-of-care worldwide.
Contact
Angela Edwards Investor Relations or Graeme Fallet Chief Financial Officer
Ventracor Limited
